Results 141 to 150 of about 62,260 (164)

Sirolimus use in allogeneic hematopoietic cell transplant recipients: assessing its senotherapeutic role in a high risk population. [PDF]

Front Aging
El Jurdi N, ElHusseini H, Cao Q, Klinger T, Shapiro E, Cömert M, Juckett M, Holtan SG, Yousefzadeh MJ.   +8 more
europepmc   +1 more source

Diffuse red-brown papules in a toddler. [PDF]

JAAD Case Rep
Phong CH, Kasheri E, Lee BA, Smith J.
europepmc   +1 more source

Immunosuppression Drugs Exhibit Differential Effects on Endothelial Cell Function. [PDF]

J Vasc Res
Elezaby A, Dexheimer R, Wu D, Chan SY, Tacco IR, Chen IY, Sayed N, Sallam K.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Molecular actions of sirolimus: sirolimus and mTor

Transplantation Proceedings, 2003
Recent therapeutic strategies to combat organ allograft rejection have focused on T-cell signaling pathways and the molecules that comprise them. The macrolide antibiotic produced by the bacterium Streptomyces hygroscopicus, known as sirolimus or rapamycin, has shown great therapeutic potential in the transplant setting.
R A, Kirken, Y L, Wang
openaire   +2 more sources

Sirolimus

Reactions Weekly, 2018
  +5 more sources

Sirolimus

Reactions Weekly, 2007
  +5 more sources

Sirolimus

Reactions Weekly, 2023
  +5 more sources

Sirolimus

Reactions Weekly, 2016
  +6 more sources

Sirolimus

Reactions Weekly, 2020
openaire   +2 more sources